Roivant's autoimmune drug succeeds in two pivotal trials, setting up 2027 filing
Roivant Sciences on Wednesday checked off another milestone in its attempt to build a franchise drug in autoimmune diseases.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Source link







